Back to Search Start Over

Nuclear medicine and biology

Authors :
David Brasse
Lionel Thomas
Pierre Mangin
François Lanza
Nicolas Receveur
Patrice Marchand
Patrice Laquerriere
Virgile Bekaert
Ali Ouadi
Christian Gachet
Institut Pluridisciplinaire Hubert Curien (IPHC)
Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)
Département Recherches Subatomiques (DRS-IPHC)
Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS)
Biologie et pharmacologie des plaquettes sanguines: hémostase, thrombose, transfusion (http://www.u949.inserm.fr/)
Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS
Centre de REcherches sur les Stratégies Economiques (EA 3190) (CRESE)
Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC)
Centre de biophysique moléculaire (CBM)
Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Biologie et Pharmacologie des Plaquettes sanguines : hémostase, thrombose, transfusion (BPP)
Université de Strasbourg (UNISTRA)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)
Domaine expérimental d'Époisses (DIJ EPOISSES)
Institut National de la Recherche Agronomique (INRA)
Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)
Etablissement Français du Sang - Grand Est (EFS - alsace strasbourg)
Fédération de Médecine Translationnelle de Strasbourg (FMTS)
Université de Strasbourg (UNISTRA)
UMR S949
Institut National de la Santé et de la Recherche Médicale (INSERM)
Brasse, David
Université de Strasbourg (UNISTRA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)
Source :
Nuclear Medicine and Biology, Nuclear Medicine and Biology, Elsevier, 2018, 61, pp.21-27. ⟨10.1016/j.nucmedbio.2018.03.003⟩, Nuclear Medicine and Biology, 2018, 61, pp.21-27. ⟨10.1016/j.nucmedbio.2018.03.003⟩
Publication Year :
2018
Publisher :
Elsevier BV, 2018.

Abstract

Platelets play a major role in thrombo-embolic diseases, notably by forming a thrombus that can ultimately occlude a vessel. This may provoke ischemic pathologies such as myocardial infarction, stroke or peripheral artery diseases, which represent the major causes of death worldwide. The aim of this study was to evaluate the specificity of radiolabeled Rat-Anti-Mouse antibody (RAM.1). Methods We describe a method to detect platelets by using a RAM.1 coupled with the chelating agent hydrazinonicotinic acid (HYNIC) conjugated to 99mTc, for Single Photon Emission Computed Tomography (SPECT). To induce platelet accumulation at a site of interest, we used a mouse model of FeCl3 induced injury of the carotid artery. 90 min after i.v. injection of [99mTc][Tc(HYNIC)-RAM.1], biodistribution of the radiolabeled RAM.1 was assessed, SPECT imaging and histological analysis were performed on the mice that underwent FeCl3-induced vessel damage. Results We demonstrated a quick and strong affinity of the radiolabeled RAM.1 for the platelet thrombus. Results clearly demonstrated the ability of this radioimmunoconjugate for detecting thrombi from 10 min post injection with an exceptional thrombi uptake. Using FeCl3, the median ratio between the thrombus and the background was 12.4 (range 9.3–42.3) as compared to 1.0 (range: 0.86–2.7) p

Details

ISSN :
09698051
Volume :
61
Database :
OpenAIRE
Journal :
Nuclear Medicine and Biology
Accession number :
edsair.doi.dedup.....c99c6ffc66db6fdb8a1326aa3fa80100
Full Text :
https://doi.org/10.1016/j.nucmedbio.2018.03.003